JPO | GenomeWeb

JPO

Alnylam Pharmaceuticals this week announced that the Japanese Patent Office has upheld certain key claims within the company's Tuschl-II patent during invalidation proceedings initiated at the request of Bio Think-Tank, a Japanese company.

Silence Therapeutics said last week that it has received a Japanese patent covering methods for screening a therapeutic agent to treat diseases, such as cancer, related to increased Pl3-kinase pathway activity.

The patent claims siRNAs containing proprietary 2’-O-methyl structures.

The patent covers a proprietary nucleic acid condensing and delivery peptide motif, as well as its use with therapeutic nucleic acids.

According to Alnylam, the patent "includes 38 claims broadly covering compositions, methods, uses, and systems for double-stranded RNAs."

The patent application — 2003-532675 — is owned by the Max Planck Institute, but is exclusively licensed to miRNA drug developer and Alnylam/Isis joint venture Regulus Therapeutics.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.